Pull to refresh
Logo
What Changed
Following Why Sign Up
BioNTech mRNA cancer immunotherapy misses first goal in head and neck trial

BioNTech mRNA cancer immunotherapy misses first goal in head and neck trial

New Capabilities

BNT113 plus Keytruda missed the trial's progression-free survival goal; survival data are still to come as other BioNTech programs report results

October 13th, 2026: AHEAD-MERIT trial misses PFS endpoint

Overview

Updated Oct 30

BioNTech's mRNA cancer drug BNT113, added to Merck's Keytruda, did not hold off HPV16-positive head and neck cancer longer than Keytruda alone. The miss, reported Oct. 13, was the first of the Phase 2/3 AHEAD-MERIT trial's two main goals, and US-listed BioNTech shares fell about 7% that day.

The trial continues to measure overall survival, and a clear gain there would still make the study positive under its design. A late-October review of BioNTech's cancer pipeline found a split picture. The Phase 3 DYNASTY-Breast02 study of trastuzumab pamirtecan met its main goal, and a pumitamig-docetaxel combination showed a 36.7% confirmed response rate in 30 lung cancer patients.

Why it matters

A survival miss would leave BioNTech's mRNA cancer push without a late-stage win and put more weight on its other drugs.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

7%
BioNTech share drop after PFS miss
Shares fell about 7% on the announcement day after sliding up to 6.1% in premarket trading, headed for a fifth decline in six sessions.
Pending
Overall survival readout
The trial continues to evaluate OS, the second dual primary endpoint.
2
Dual primary endpoints in AHEAD-MERIT
PFS was missed; OS evaluation continues under the pre-specified statistical design.
$125
Citi price target maintained
Citi kept its Buy rating and $125 target on BioNTech after the miss, citing the survival endpoint.
36.7%
Pumitamig combination response rate
Confirmed objective response rate with docetaxel across 30 efficacy-evaluable patients in the ROSETTA Lung-107 study, cited in an Oct. 28 pipeline review.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Özlem Türeci
Özlem Türeci
Co-founder and Chief Medical Officer, BioNTech
Leading the company's oncology strategy
GM
Geoffrey Meacham
Biotech analyst, Citi
Citi maintained its Buy rating and $125 price target on BioNTech after the PFS miss
 Daina Graybosch
Daina Graybosch
Biotech analyst, Leerink Partners
Tracking BioNTech's pipeline strategy
 Evan David Seigerman
Evan David Seigerman
Biotech analyst, BMO Capital Markets
Cautious on the overall survival readout after the PFS miss

Organizations Involved

BioNTech
BioNTech
Biopharmaceutical company
Developer of BNT113, the mRNA cancer immunotherapy under evaluation

German biotech that developed the COVID-19 vaccine Comirnaty with Pfizer and is now focused on mRNA cancer treatments.
The Merc
The Merc
Mixed-use development
Markets pembrolizumab (Keytruda), the control arm and combination partner in the AHEAD-MERIT trial

Merck & Co. developed pembrolizumab (Keytruda), the checkpoint inhibitor used as the control and combination partner in the AHEAD-MERIT trial.
Bristol Myers Squibb
Bristol Myers Squibb
Pharmaceutical company
Partner on pumitamig, BioNTech's bispecific cancer drug

Partnering with BioNTech on pumitamig, a bispecific cancer treatment that analysts say is now BioNTech's most important pipeline asset.

Timeline

2026 October 2026

5 events Latest: October 13th, 2026 · 4 weeks ago
Tap a bar to jump to that date

  1. AHEAD-MERIT trial misses PFS endpoint

    Latest Clinical Trial

    BNT113 plus pembrolizumab did not show a statistically significant improvement in progression-free survival versus pembrolizumab alone. An independent data monitoring committee recommended continuing for the overall survival analysis.

  2. Citi maintains Buy rating and $125 price target on BioNTech

    Market Analysis

    After the PFS miss, Citi kept its Buy rating and $125 target, saying an overall survival benefit would preserve a meaningful development path.

  3. BioNTech shares fall about 7% on trial miss

    Market

    US-listed shares fell about 7% on the day of the announcement, headed for their fifth decline in six sessions.

  4. Analyst flags BNT113 evidence as sparse

    Analysis

    Leerink analyst Daina Graybosch wrote that evidence supporting BNT113's activity was sparse when the Phase 3 study launched.

  5. BioNTech reports colorectal cancer setback

    Clinical Trial

    The company reported a study setback in colorectal cancer earlier this year, adding to its oncology pipeline challenges.

Scenarios

1

BNT113 extends survival, trial declared positive

Possible Resolves by Q2 2028

Discussed by: BioNTech, BMO Capital Markets analysts

The IDMC recommended continuing the trial. If OS shows a statistically significant improvement, the trial is positive under the pre-specified design. Precedent exists: Keytruda itself missed PFS in an earlier head and neck cancer trial but improved OS. Türeci argued that immune-mediated antitumor effects can build and deepen over time, potentially showing durable benefits.

2

BNT113 fails to extend survival

Likely Resolves by Q2 2028

Discussed by: BMO Capital Markets analysts, Citi analyst Geoffrey Meacham

BMO analysts said the PFS miss made them 'significantly' less confident in OS. Many trials that miss PFS later fail OS. Meacham noted that head and neck cancer is heterogeneous and heavily immunosuppressed, making incremental efficacy over pembrolizumab challenging despite the HPV16 target.

3

OS shows trend without significance, BNT113 deprioritized

Possible Resolves by Q2 2028

Discussed by: Leerink Partners analyst Daina Graybosch

If OS shows a favorable trend without statistical significance, BioNTech may narrow development to a specific patient subgroup or shift resources to pumitamig, its bispecific cancer drug. Graybosch has said BioNTech is already leaning on pumitamig.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2016-2026

Cancer immunotherapies that missed PFS and won on survival

Merck's pembrolizumab (Keytruda) is the control arm in AHEAD-MERIT. In reporting the Oct. 13, 2026 BNT113 result, Reuters noted that previous cancer immunotherapies have won regulatory approval after missing progression-free survival targets but succeeding on overall survival goals.

Then

Regulators have accepted overall survival as the stronger measure of benefit in cancer trials.

Now

A survival gain can outweigh a missed progression-free survival endpoint.

Why this matters now

BioNTech is hoping BNT113 follows the same pattern: miss PFS but succeed on OS.

2013-2014

GSK MAGE-A3 cancer vaccine (2013-2014)

GSK's MAGE-A3 antigen-specific cancer immunotherapeutic failed Phase 3 trials in melanoma and non-small cell lung cancer, showing no benefit over placebo.

Then

GSK discontinued the program in 2014.

Now

It became a cautionary tale for therapeutic cancer vaccines, which have struggled to generate meaningful immune responses against established tumors.

Why this matters now

BNT113 uses mRNA technology rather than a protein antigen, but faces the same fundamental challenge: generating a durable immune response against an established tumor.

Sources

(16)
+10
BioPharma Dive BioNTech BioPharma Dive via Yahoo Finance Fierce Biotech Endpoints News MarketWatch Clinical Trials Arena Nasdaq GenomeWeb Reuters via 95 KQDS Investegate Market Briefs TradingView News ad-hoc-news.de Reuters Yahoo Finance